Yüklüyor......
Response to Lapatinib-Capecitabine combination in a young patient with recurrent HER2-positive breast cancer refractory to two lines of therapy with anti-HER2 drugs
HER2-positive breast cancer is an aggressive tumour that affects approximately one in five breast cancer women. Clinical studies have shown that HER2-positive cancer have different characteristics from other mammary tumors: a more rapid progression of the disease, an earlier age of onset (women of c...
Kaydedildi:
| Asıl Yazarlar: | , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
AboutScience Srl
2018-10-01
|
| Seri Bilgileri: | AboutOpen |
| Konular: | |
| Online Erişim: | https://journals.aboutscience.eu/index.php/aboutopen/article/view/135 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|